Skip to main content

Table 2 Simple linear regression analysis for the weight-corrected PB C/D ratio

From: Factors affecting serum phenobarbital concentration changes in pediatric patients receiving elixir and powder formulations

  β 95% CI p-value
Male 0.094 −0.168 - 0.355 0.477
Age 0.390 0.147–0.632 0.002
Body weight 0.443 0.207–0.679 < 0.001
PB dose 0.163 −0.097 - 0.422 0.214
Number of daily PB doses 0.116 −0.145 - 0.377 0.376
ALB 0.133 −0.128 - 0.393 0.312
AST 0.151 −0.109 - 0.411 0.249
ALT −0.135 −0.395 - 0.125 0.304
LDH 0.259 0.006–0.513 0.045
γGTP 0.249 −0.005 - 0.504 0.055
BUN −0.037 −0.300 - 0.226 0.779
Scr 0.037 −0.226 - 0.300 0.780
Interacting drug use (VPA or amiodarone) 0.516 0.291–0.741 < 0.001
Dosage formulation −0.225 −0.481 - 0.032 0.085
Administration route −0.134 −0.395 - 0.126 0.306
  1. C/D serum concentration/dose, VPA valproic acid, PB phenobarbital, ALB serum albumin, AST aspartate aminotransferase, ALT alanine aminotransferase, LDH lactate dehydrogenase, γGTP γ-glutamyl transpeptidase, BUN blood urea nitrogen, Scr serum creatinine β standardized partial regression coefficient, CI confidence interval
  2. Simple linear regression analysis was performed using the weight-corrected PB C/D ratio as the dependent variable and patient background as the explanatory variable